Get 50% OFF This Monsoon!
Sotac Pharmaceuticals
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Sotac Pharmaceuticals Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name of 'M/s Sotac Pharmaceuticals', pursuant to a Deed of Partnership dated October 28, 2015. Thereafter 'M/s. Sotac Pharmaceuticals' was converted from Partnership Firm to a Private Limited Company in the name of 'Sotac Pharmaceuticals Private Limited' dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat. Later on, Company converted into a Public Limited Company and the name of Company was changed to 'Sotac Pharmaceuticals Limited' dated November 22, 2022 issued by Registrar of Companies, Ahmedabad.
The Company is a part of SOTAC Group, based at Gujarat and is engaged in manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis. The Company is pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, beta-lactam coated tablets, beta-lactam uncoated tablets, Non Beta-Lactam (general) capsules, beta-lactam capsules, oral liquid, dry syrup and external preparations such as nasal spray, relief spray and cream.
The Company's therapeutic portfolio include Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, AntiAllergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, AntiPyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams & Non-IP-Lactams, Anti-Fungal, Cephalosporin. Consequently, as a Group, it cater to a wide spectrum of companies for formulation development, clinical batch production, commercial scale productions.
The Company commenced manufacturing facility in year 2017, which had an installed capacity to manufacture 90 Crore tables / year, 14 Crore Capsules / year. Later, in 2022, the Company acquired 71% holding in SOTAC Healthcare Private Limited and 100% holding in SOTAC Research Private Limited, thus making them as wholly owned Subsidiary Companies in April, 2022. Thereafter, it started a new venture, SOTAC Lifescience Private Limited and held 51% of total paid-up capital in it.
The Company is planning to come out with a Initial Public offer consisting of upto 30,00,000 Equity Shares through Fresh issue.
Sotac Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Sotac Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Sotac Pharmaceuticals is valued compared to its competitors.
Sotac Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Sotac Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Sotac Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Sotac Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Sotac Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Sotac Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Sotac Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Sotac Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Sotac Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Sotac Pharmaceuticals Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Sotac Pharmaceuticals shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Sotac Pharmaceuticals ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Sotac Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Sotac Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Sotac Pharmaceuticals .
The balance sheet presents a snapshot of Sotac Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.